Research programme: protein therapeutics - Haemacure Corporation

Drug Profile

Research programme: protein therapeutics - Haemacure Corporation

Latest Information Update: 07 Feb 2011

Price : $50

At a glance

  • Originator Haemacure Corporation
  • Class Enzymes; Proteins
  • Mechanism of Action Enzyme replacements; Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological disorders; Metabolic disorders

Most Recent Events

  • 07 Feb 2011 Discontinued for Metabolic disorders in Canada (Parenteral)
  • 07 Feb 2011 Discontinued for Haematological disorders in Canada (Parenteral)
  • 07 Mar 2008 Early research in Metabolic disorders in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top